Welcome to our dedicated page for TC BioPharm (Holdings) news (Ticker: TCBP), a resource for investors and traders seeking the latest updates and insights on TC BioPharm (Holdings) stock.
TC BioPharm (Holdings) PLC (TCBP) generates a steady flow of news as a clinical-stage biopharmaceutical company developing allogeneic gamma-delta T cell therapies for cancer and other indications. News coverage on this page focuses on the company’s clinical progress, strategic initiatives, and capital markets developments, helping readers follow how its gamma-delta T cell platform is advancing from early-stage research into later-stage trials and potential new indications.
Many updates relate to TCB008, the company’s lead gamma-delta T cell therapy candidate. Articles highlight milestones in the ACHIEVE Phase II UK clinical trial, including completion of dosing in Cohort A for relapsed or refractory acute myeloid leukemia patients, initial dosing and follow-up in Cohort B minimal residual disease patients, safety findings with no reported drug-related adverse events, and efficacy signals such as stable disease and complete molecular remission in at least one MRD patient. These reports provide insight into how TCB008 is performing in challenging hematologic malignancies.
Other news items cover strategic and corporate actions, such as TC BioPharm’s intention to conduct proof-of-concept preclinical studies of TCB008 in H5N1 (avian “bird flu”), a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company with an FDA-approved glaucoma treatment, and operational changes including a shift toward a CDMO-based manufacturing model and associated workforce reductions. Capital markets announcements, including an ADS ratio change and the company’s transition from Nasdaq to trading on OTC Markets, are also reported.
Investors and observers can use this news feed to track clinical data readouts, expansion into new therapeutic areas, proposed M&A activity, and listing or ADS structure changes. For those following TCBP, revisiting this page offers a consolidated view of how the company’s gamma-delta T cell programs and broader strategy evolve over time.
TC Biopharm announced positive interim results from its Phase 1a/2b study of TCB-002, OmnImmune®, targeting relapse/refractory Acute Myeloid Leukemia (AML). Out of 7 treated patients, 50% in the higher dose cohort achieved complete responses, with no serious safety concerns reported. The study evaluated safety and tolerability, indicating OmnImmune® is a promising therapeutic option for late-stage AML patients. The company plans to expand trials in 2022 and report further data, highlighting the potential of gamma-delta T cell therapies in treating blood cancers.
TC Biopharm, a clinical-stage biotechnology company, will host a corporate update call on March 8, 2022, at 9:00 am ET. The call will focus on recent milestones, corporate developments, and clinical plans, with CEO Bryan Kobel facilitating the event. Investors are encouraged to submit questions ahead of time at IR@tcbiopharm.com. The company, known for its innovative allogeneic gamma-delta T cell therapies for cancer and viral infections, is currently conducting pivotal clinical trials for its therapies.
TC Biopharm (NASDAQ: TCBP) announced the appointment of four new independent members, Mark Bonyhadi, James Culverwell, Arlene Morris, and Edward Niemczyk, to its Board of Directors, effective post-IPO. This increases the board's membership to seven. The CEO, Bryan Kobel, expressed confidence in their leadership and expertise in drug commercialization and capital markets to drive the company's strategy in developing gamma-delta T cell therapies for cancer and viral infections.
TC Biopharm has successfully closed its initial public offering, raising approximately $17.5 million through the sale of 4,117,648 ADSs and warrants to purchase up to 8,235,296 ADSs. The offering included an additional 1,235,294 warrants purchased by underwriters at an exercise price of $4.25. The proceeds will finance clinical trials for OmnImmune® and ImmuniStim® therapies, designed to treat acute myeloid leukemia and COVID-19, respectively, alongside other operational and research costs.
TC BioPharm, a clinical stage biotechnology company, announces its American Depositary Shares will start trading on the Nasdaq under the ticker symbol TCBP as of February 11, 2022. This listing is a significant milestone, allowing the company greater access to capital markets and increased visibility. TC BioPharm focuses on developing gamma-delta T cell therapies for cancer and viral infections, with key products including OmnImmune®, currently in late-stage clinical trials for blood cancer. The company aims to enhance shareholder value through this listing.
TC Biopharm announced the pricing of its initial public offering (IPO) of 4,117,648 American Depositary Shares (ADSs) and warrants, aiming for gross proceeds of approximately $17.5 million. The offering price is set at $4.25 per combined unit of one ADS and two Warrants. The company plans to utilize the funds for clinical trials in treatments for acute myeloid leukemia and viral infections, alongside research and development for future therapies. The IPO is expected to close around February 15, 2022, with trading on Nasdaq starting on February 11, 2022.